Clinical trial NCT00701766: BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia
Official title: An Open, Randomised Clinical Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Efficacy, Safety and Pharmacokinetics of Repeated Three-week Courses of a Single Dose i.v. BI 2536 on Day 1 in Comparison to Single Doses i.v. BI 2536 on Days 1, 2 and 3 in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Leukemia, Myeloid, Acute
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2008-06-19
Enrollment: 71
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The present trial will be performed to determine the MTD and to evaluate the efficacy of BI 2536 in the treatment of elderly patients with relapsed or refractory AML. Different schedules will be compared to identify the better dosing schedule for the further development programme of BI 2536. Dose escalation starting with the maximum tolerated dose previously determined in patients with advanced solid cancers will be performed to determine the maximum tolerated dose for AML patients.


Eligibility criteria: Inclusion Criteria:

* Male or female patients older than 60 years of age
* Patient with confirmed AML (except for APL) according to the WHO definition who relapsed after or are refractory to prior chemotherapy
* Leukocyte count \<= 25,000 /mcl (25 x 10e9/Liter)
* Patient not eligible for intensive treatment options
* Life expectancy \>= 2 months
* Eastern co-operative oncology group performance score of 2 or less
* Signed written informed consent consistent with international conference on harmonisation - good clinical practice (ICH-GCP) and local legislation

Exclusion Criteria:

* Patient with acute promyelocytic leukaemia (APL, AML of the French-American-British (FAB) classification subtype M3)
* Hypersensitivity to the trial drug or the excipients
* Secondary malignancy requiring therapy
* Known central nervous system involvement
* Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal, or AST or ALT greater than 5 times the upper limit of normal in case of known liver involvement
* Bilirubin greater than 1.5 mg/dl (\> 26 mcmol/l, SI unit equivalent)
* Serum creatinine greater than 2.0 mg/dl
* Concomitant intercurrent illness, which would compromise the evaluation of efficacy or safety of the trial drug, e.g. active severe infection, unstable angina pectoris or cardiac arrhythmia
* Psychiatric illness or social situation that would limit compliance with trial requirements
* Concomitant therapy, which is considered relevant for the evaluation of the efficacy or safety of the trial drug
* Chemotherapy (except hydroxyurea) or immunotherapy or treatment with any other investigational drug within the past four weeks prior to treatment with the trial drug
* Persistence of toxicities of prior anti-leukaemia therapies which are deemed to be clinically relevant
* Patients who are sexually active and unwilling to use a medically acceptable method of contraception during the trial (hormonal contraception, intrauterine device, condom with spermicide, etc.)
* Patient unable to comply with the protocol

Primary outcomes:
measure: Maximum tolerated dose Best objective response
timeFrame: 3 weeks, throughout the study period
Secondary outcomes:
measure: Event free survival, Overall survival, Remission duration, BI 2536 plasma concentrations, Incidence and intensity of adverse events graded according to CTCAE, PD, Incidence of DLT
timeFrame: throughout the study period
Other outcomes:
Locations:
city: Innsbruck
country: Austria
facility: 1216.20.43001 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 1216.20.43002 Boehringer Ingelheim Investigational Site
city: Bonn
country: Germany
facility: 1216.20.49006 Boehringer Ingelheim Investigational Site
city: Frankfurt
country: Germany
facility: 1216.20.49002 Boehringer Ingelheim Investigational Site
city: Freiburg
country: Germany
facility: 1216.20.49003 Boehringer Ingelheim Investigational Site
city: Hannover-Heideviertel
country: Germany
facility: 1216.20.49004 Boehringer Ingelheim Investigational Site
city: Heidelberg
country: Germany
facility: 1216.20.49007 Boehringer Ingelheim Investigational Site
city: Münster
country: Germany
facility: 1216.20.49005 Boehringer Ingelheim Investigational Site
city: Ulm
country: Germany
facility: 1216.20.49001 Boehringer Ingelheim Investigational Site
Study officials:
affiliation: Boehringer Ingelheim
name: Boehringer Ingelheim
role: STUDY_CHAIR
References: